Prevalence of "Ghost Infarct Core" after Endovascular Thrombectomy.


Journal

AJNR. American journal of neuroradiology
ISSN: 1936-959X
Titre abrégé: AJNR Am J Neuroradiol
Pays: United States
ID NLM: 8003708

Informations de publication

Date de publication:
07 Mar 2024
Historique:
received: 10 04 2023
accepted: 01 12 2023
medline: 11 3 2024
pubmed: 26 1 2024
entrez: 25 1 2024
Statut: epublish

Résumé

Baseline CTP sometimes overestimates the size of the infarct core ("ghost core" phenomenon). We investigated how often CTP overestimates infarct core compared with 24-hour imaging, and aimed to characterize the patient subgroup in whom a ghost core is most likely to occur. Data are from the randomized controlled ESCAPE-NA1 trial, in which patients with acute ischemic stroke undergoing endovascular treatment were randomized to intravenous nerinetide or placebo. Patients with available baseline CTP and 24-hour follow-up imaging were included in the analysis. Ghost infarct core was defined as CTP core volume minus 24-hour infarct volume > 10 mL). Clinical characteristics of patients with versus without ghost core were compared. Associations of ghost core and clinical characteristics were assessed by using multivariable logistic regression. A total of 421 of 1105 patients (38.1%) were included in the analysis. Forty-seven (11.2%) had a ghost core > 10 mL, with a median ghost infarct volume of 13.4 mL (interquartile range 7.6-26.8). Young patient age, complete recanalization, short last known well to CT times, and possibly male sex were associated with ghost infarct core. CTP ghost core occurred in ∼1 of 10 patients, indicating that CTP frequently overestimates the infarct core size at baseline, particularly in young patients with complete recanalization and short ischemia duration.

Sections du résumé

BACKGROUND AND PURPOSE OBJECTIVE
Baseline CTP sometimes overestimates the size of the infarct core ("ghost core" phenomenon). We investigated how often CTP overestimates infarct core compared with 24-hour imaging, and aimed to characterize the patient subgroup in whom a ghost core is most likely to occur.
MATERIALS AND METHODS METHODS
Data are from the randomized controlled ESCAPE-NA1 trial, in which patients with acute ischemic stroke undergoing endovascular treatment were randomized to intravenous nerinetide or placebo. Patients with available baseline CTP and 24-hour follow-up imaging were included in the analysis. Ghost infarct core was defined as CTP core volume minus 24-hour infarct volume > 10 mL). Clinical characteristics of patients with versus without ghost core were compared. Associations of ghost core and clinical characteristics were assessed by using multivariable logistic regression.
RESULTS RESULTS
A total of 421 of 1105 patients (38.1%) were included in the analysis. Forty-seven (11.2%) had a ghost core > 10 mL, with a median ghost infarct volume of 13.4 mL (interquartile range 7.6-26.8). Young patient age, complete recanalization, short last known well to CT times, and possibly male sex were associated with ghost infarct core.
CONCLUSIONS CONCLUSIONS
CTP ghost core occurred in ∼1 of 10 patients, indicating that CTP frequently overestimates the infarct core size at baseline, particularly in young patients with complete recanalization and short ischemia duration.

Identifiants

pubmed: 38272571
pii: ajnr.A8113
doi: 10.3174/ajnr.A8113
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

291-295

Informations de copyright

© 2024 by American Journal of Neuroradiology.

Auteurs

Johanna M Ospel (JM)

From the Department of Diagnostic Imaging (J.M.O., M.D.H., M.G.), University of Calgary, Calgary, Alberta, Canada.
Department of Clinical Neurosciences (J.M.O., N.R., L.R., M.D.H., M.G.), University of Calgary, Calgary, Alberta, Canada.

Nathaniel Rex (N)

Department of Clinical Neurosciences (J.M.O., N.R., L.R., M.D.H., M.G.), University of Calgary, Calgary, Alberta, Canada.
Department of Diagnostic Imaging (N.R.), Brown University, Providence, Rhode Island.

Leon Rinkel (L)

Department of Clinical Neurosciences (J.M.O., N.R., L.R., M.D.H., M.G.), University of Calgary, Calgary, Alberta, Canada.
Department of Neurology (L.R.), Amsterdam University Medical Center, Amsterdam, the Netherlands.

Nima Kashani (N)

Department of Neurosurgery (N.K., M.E.K.), University of Saskatchewan, Saskatoon, Saskatchewan, Canada.

Brian Buck (B)

University of Alberta Hospital (B.B., J.R.), Edmonton, Alberta, Canada.

Jeremy Rempel (J)

University of Alberta Hospital (B.B., J.R.), Edmonton, Alberta, Canada.

Demetrios Sahlas (D)

McMaster University (D.S.), Hamilton, Ontario, Canada.

Michael E Kelly (ME)

Department of Neurosurgery (N.K., M.E.K.), University of Saskatchewan, Saskatoon, Saskatchewan, Canada.

Ron Budzik (R)

Ohio Health (R.B.), Riverside Methodist Hospital, Columbus, Ohio.

Michael Tymianski (M)

NoNO Inc. (M.T.) Toronto, Ontario, Canada.

Michael D Hill (MD)

From the Department of Diagnostic Imaging (J.M.O., M.D.H., M.G.), University of Calgary, Calgary, Alberta, Canada.
Department of Clinical Neurosciences (J.M.O., N.R., L.R., M.D.H., M.G.), University of Calgary, Calgary, Alberta, Canada.

Mayank Goyal (M)

From the Department of Diagnostic Imaging (J.M.O., M.D.H., M.G.), University of Calgary, Calgary, Alberta, Canada mgoyal@ucalgary.ca.
Department of Clinical Neurosciences (J.M.O., N.R., L.R., M.D.H., M.G.), University of Calgary, Calgary, Alberta, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH